J
Jiaxin Wu
Researcher at Chinese Academy of Sciences
Publications - 21
Citations - 264
Jiaxin Wu is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Prodrug & Anaplastic lymphoma kinase. The author has an hindex of 8, co-authored 19 publications receiving 182 citations. Previous affiliations of Jiaxin Wu include University of Science and Technology of China & Hefei Institutes of Physical Science.
Papers
More filters
Journal ArticleDOI
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
Hong Wu,Hong Wu,Aoli Wang,Aoli Wang,Wei Zhang,Beilei Wang,Cheng Chen,Wenchao Wang,Chen Hu,Zi Ye,Zheng Zhao,Li Wang,Xixiang Li,Kailin Yu,Juan Liu,Jiaxin Wu,Jiaxin Wu,Xiao-E Yan,Peng Zhao,Jinhua Wang,Chu Wang,Ellen Weisberg,Nathanael S. Gray,Cai-Hong Yun,Jing Liu,Liang Chen,Qingsong Liu,Qingsong Liu +27 more
TL;DR: Ibrutinib strongly affected EGFR mediated signaling pathways and induced apoptosis and cell cycle arrest (G0/G1) in mutant EGFR but not wt EGFR cells, but only slowed down tumor progression in PC-9 and H1975 xenograft models.
Journal ArticleDOI
Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia
Xixiang Li,Aoli Wang,Aoli Wang,Kailin Yu,Kailin Yu,Ziping Qi,Cheng Chen,Wenchao Wang,Chen Hu,Hong Wu,Hong Wu,Jiaxin Wu,Jiaxin Wu,Zheng Zhao,Juan Liu,Fengming Zou,Li Wang,Beilei Wang,Wei Wang,Shanchun Zhang,Jing Liu,Qingsong Liu +21 more
TL;DR: In the in vivo studies 18 demonstrated a good bioavailability and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity, indicating a potential to avoid the FLT3/c-KIT dual inhibition induced myelosuppression toxicity.
Journal ArticleDOI
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
Hong Wu,Chen Hu,Aoli Wang,Aoli Wang,Ellen Weisberg,Wenchao Wang,Cheng Chen,Zheng Zhao,Kailin Yu,Jing Liu,Jiaxin Wu,Jiaxin Wu,Atsushi Nonami,Li Wang,Beilei Wang,Richard Stone,Suiyang Liu,James D. Griffin,Qingsong Liu,Qingsong Liu +19 more
TL;DR: It is found that only FLT3-internal tandem duplication mutant AML cell lines were sensitive to ibrutinib, and BTK kinase inhibition through use of a small molecule inhibitor like ibrUTinib led only to moderate inhibition of proliferation of U937 cells with no apparent activity against other AMLcell lines.
Journal ArticleDOI
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML
Aoli Wang,Xixiang Li,Cheng Chen,Cheng Chen,Hong Wu,Ziping Qi,Chen Hu,Chen Hu,Kailin Yu,Kailin Yu,Jiaxin Wu,Jiaxin Wu,Juan Liu,Xiaochuan Liu,Zhenquan Hu,Wei Wang,Wenliang Wang,Wenliang Wang,Wenchao Wang,Li Wang,Li Wang,Beilei Wang,Beilei Wang,Qingwang Liu,Lili Li,Jian Ge,Tao Ren,Shanchun Zhang,Ruixiang Xia,Jing Liu,Qingsong Liu +30 more
TL;DR: A new type II FLT3 kinase inhibitor, compound 14 (CHMFL-FLT3-213), is discovered, which exhibited highly potent inhibitory effects against FLT 3-ITD mutant and associated oncogenic mutations.
Journal ArticleDOI
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
Aoli Wang,Aoli Wang,Hong Wu,Hong Wu,Cheng Chen,Chen Hu,Ziping Qi,Wenchao Wang,Kailin Yu,Xiaochuan Liu,Xiaochuan Liu,Fengming Zou,Zheng Zhao,Jiaxin Wu,Jiaxin Wu,Juan Liu,Feiyang Liu,Feiyang Liu,Li Wang,Richard Stone,Ilene A. Galinksy,James D. Griffin,Shanchun Zhang,Ellen Weisberg,Jing Liu,Qingsong Liu +25 more
TL;DR: This work identifies the well-established orally available AKT inhibitor, A674563, as a dual suppressor of AKT and FLT3-ITD, and suggests that A67 4563 might be a potential drug candidate for overcomingFLT3 ligand-mediated drug resistance in FLT 3- ITD positive AML.